Are sustained-release drugs the answer to ophthalmology’s topical drop problem?
Alice T. Epitropoulos | | Longer Read
Ocular drugs are only as good as their delivery. The ideal delivery system is designed to enhance bioavailability, permeate ocular barriers, and provide controlled and sustained drug release – where the therapeutic is needed. Strides have been made in achieving these goals in both the anterior and posterior segments in recent years, and additional advances are being achieved with each new approval. Topical drops remain widely used, but these standard treatments can be challenging for many of our patients. Adherence to topical drop regimens, either for chronic treatment or in the postoperative setting, is known to be poor. Some of our patients have a real fear of putting drops in their eyes, while others may have physical limitations, such as poor dexterity or a tremor, that makes it difficult to properly instill the drops, particularly for post-surgical patients who may have limited experience with their use.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine